Modality
Nanobody
MOA
PCSK9i
Target
EZH2
Pathway
Proteasome
CMLMMCTCL
Development Pipeline
Preclinical
Oct 2017
→ Feb 2031
PreclinicalCurrent
NCT06187141
1,657 pts·CTCL
2017-10→2029-12·Not yet recruiting
NCT06999943
731 pts·MM
2019-12→2031-02·Active
2,388 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-12-063.7y awayInterim· CTCL
2031-02-064.9y awayInterim· MM
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2029-12-06 · 3.7y away
CTCL
Interim
2031-02-06 · 4.9y away
MM
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06187141 | Preclinical | CTCL | Not yet recr... | 1657 | EDSS |
| NCT06999943 | Preclinical | MM | Active | 731 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα | |
| Capicilimab | Structure Ther | Phase 1 | EGFR |